Drug Database
IB

ibuprofen (ibuprofen, Nordmark / ibuprofen, Pacific / ibuprofen, Bracco)

✓ Approved

Bracco · PTGS1 · Small Molecule

What is ibuprofen?

ibuprofen is a small molecule developed by Bracco. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namesibuprofen, Nordmark, ibuprofen, Pacific, ibuprofen, Bracco
CompanyBracco
Drug ClassSmall Molecule
Molecular TargetPTGS1, PTGS2
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

ibuprofen acts on 2 molecular targets:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

ibuprofen is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Gastrointestinal disordersAbdominal pain✓ Approved
Hepatobiliary disordersHepatitis✓ Approved

Related Research Articles

PubMedFrontiers in endocrinology2026-10-22

Diagnostic value of saline infusion test-derived biochemical parameters for primary aldosteronism subtyping.

Öztürk Yusuf Y, Karakurt Feridun F

Current clinical practice guidelines recommend adrenal venous sampling (AVS) for subtype classification in patients with primary aldosteronism (PA) who are candidates for adrenalectomy; however, AVS may be considered unnecessary in selected young patients with a high probability of unilateral disease. The additional diagnostic information provided by baseline and saline infusion test (SIT)-derived biochemical parameters when evaluated alongside clinical and radiological features remains uncertain. We aimed to compare the diagnostic performance of baseline and SIT-derived biochemical parameters for predicting unilateral PA and to evaluate the additional diagnostic information provided by each parameter when individually added to a common clinical-radiological framework. This retrospective study included 73 patients with PA (41 unilateral and 32 bilateral) who underwent successful AVS for subtype classification. Baseline plasma aldosterone concentration (PAC), baseline aldosterone-to-potassium ratio (APR), post-SIT PAC, SIT-derived APR, and the suppression index were evaluated. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis, while their associations within a common clinical-radiological model were evaluated using multivariable logistic regression analysis. Post-SIT PAC and SIT-derived APR showed the highest numerical discriminative performance among the evaluated biochemical parameters for predicting unilateral PA (AUC = 0.817 and 0.837, respectively). Adding either parameter individually to the common clinical-radiological model significantly improved model fit (likelihood-ratio p = 0.014 and p = 0.028, respectively); however, the increases in AUC were not statistically significant (ΔAUC = 0.022, p = 0.185 and ΔAUC = 0.017, p = 0.107, respectively). Post-SIT PAC and SIT-derived APR were strongly correlated (Spearman's ρ = 0.983, p < 0.001), and their ROC-derived thresholds yielded concordant classifications in 97.3% of patients. Our findings suggest that post-SIT PAC shows useful discriminative performance for predicting unilateral PA and may contribute to subtype assessment when considered alongside clinical and radiological features. These findings require validation in independent cohorts.

PubMedInternal and emergency medicine2026-10-21

Intravenous ibuprofen versus ketorolac for acute low back pain in the emergency department: a triple-blind randomized clinical trial.

Jafarkhani Mona M, Bahreini Maryam M, Rasooli Fatemeh F

Considering the frequency of recurrence in low back pain (LBP), there is no single medication group with promising efficacy in acute settings. Non-steroidal anti-inflammatory drugs (NSAIDs) provide better pain relief with rather low complications. Since ketorolac has been relatively effective, we compared its safety and efficacy with ibuprofen as an alternative for pain relief in acute LBP. In this multi-centric triple-blind randomized clinical trial, we compared intravenous (IV) ibuprofen and ketorolac in patients with acute LBP presenting to the EDs of three university hospitals. Group 1 received IV ibuprofen (800 mg), and group 2 received IV ketorolac (30 mg), based on a computerized random sequence. Trained head nurses prepared analgesics in blocks of four. Neither patients nor the researcher or the statistician knew about the medication. We applied Visual Analog Scale (VAS) for patients to score their pain at baseline and 10 and 30 min after pain medications. Of 73 enrolled patients, 39 were in the ketorolac group and 34 participants in the ibuprofen group. Pain scores were significantly lower in the ibuprofen group at both 10 min (49.6 vs 57.4; p =0.013) and 30 min (32.2 vs 40.7; p =0.038). Based on the pain intensity after 30 min, the majority of patients in the ibuprofen group (70.6%) rated their pain as mild, while only 35.9% of the ketorolac group reported pain relief to a mild level (p <0.001). The mean ED length of stay was significantly lower in the ibuprofen group, whereas rescue analgesia and adverse events were comparable between the groups. Pain intensity was significantly lower in the ibuprofen group than in the ketorolac group after 10 and 30 min, without a significant difference in side effects. Intravenous ibuprofen can serve as an acceptable alternative and might be more effective than ketorolac in acute LBP in the ED.

PubMedBMC pregnancy and childbirth2026-10-21

Acceptability and uptake of COVID-19 vaccines among pregnant and lactating women seeking services at a tertiary public hospital in Kampala, Uganda.

Katana Elizabeth B EB, Odongpiny Eva Agnes Laker EAL, Simbwa Brenda N BN, Nsubuga Edirisa J EJ et al.

Globally, several vaccines, including COVID-19 vaccines, have been routinely recommended during pregnancy and lactation. However, data on COVID-19 vaccine acceptability and uptake among pregnant and lactating women are limited in Sub-Saharan Africa. While COVID-19 is no longer a public health emergency it is important to take stock of lessons learnt to prepare for future health threats including those that disproportionately affect pregnant/lactating women. We aimed to assess acceptability and uptake of COVID-19 vaccines among pregnant and lactating women in Uganda. This was a cross-sectional study conducted among 424 pregnant and lactating women, who were seeking maternal and child health care at Kawempe National Referral Hospital in Kampala conducted between May and July 2023. We obtained data on vaccine acceptability defined as willingness to accept vaccines using interviewer-administered questionnaires. In addition, we assessed vaccination status. Factors associated with COVID-19 vaccine acceptability and uptake were evaluated using modified Poisson regression. The mean age of the respondents was 26.9 years (SD = 5.7), ranging from 14 to 45 years. Among 424 respondents, 51.6% had received at least one dose of COVID-19 vaccine, 94.1% had received tetanus toxoid vaccine, and 48.4% regardless of their vaccination status, were willing to receive COVID-19 vaccines. Only 5/212(2.4%) had received COVID-19 vaccines while lactating with none having been received during pregnancy. Factors associated with COVID-19 vaccine uptake included history of testing for COVID-19 (aPR = 1.92, CI:1.46-2.54) and having a vaccinated household member (aPR = 1.34, CI:1.03-1.84). COVID-19 vaccine willingness was significantly associated with being a household head (aPR = 2.2, CI:1.12-4.27) and having a vaccinated household member (aPR = 1.33, CI:1.04-1.76). COVID-19 vaccine acceptance among pregnant and lactating women remains suboptimal despite high acceptance of other maternal vaccines. These findings highlight the need for targeted interventions to improve the acceptance and uptake of COVID-19 vaccines, during pregnancy and lactation. Strengthening risk communication, addressing safety concerns, and leveraging trusted sources of information may enhance vaccine confidence and improve uptake during pregnancy and lactation.

PubMedCardiovascular diabetology. Endocrinology reports2026-10-21

Multidomain Autonomic Dysfunction assessed with COMPASS-31 among patients with type 2 diabetes in Zanzibar: prevalence and associated factors.

Haji Hassan Thabit HT, Ali Ramla Muhidin RM, Khamis Ahmed Gharib AG, Ramaiya Kaushik K et al.

Autonomic dysfunction is an important but frequently under-recognized complication of type 2 diabetes mellitus (T2DM), particularly in settings where objective autonomic testing is not routinely available. The Composite Autonomic Symptom Score-31 (COMPASS-31) provides a practical symptom-based approach for assessing autonomic dysfunction across multiple domains. This study compared socioeconomic, lifestyle, and clinical characteristics among adults with T2DM in Zanzibar according to COMPASS-31-defined autonomic dysfunction and examined factors associated with its presence. This hospital-based cross-sectional study included 665 adults with T2DM attending the diabetes clinic at Mnazi Mmoja Hospital, Zanzibar. Autonomic symptoms were assessed using COMPASS-31, including the orthostatic intolerance, gastrointestinal, and bladder domains. Participants were classified as having autonomic dysfunction when they met the prespecified threshold for dysfunction in at least one assessed domain. Cardiovascular autonomic neuropathy (CAN) was assessed separately using standardized cardiovascular autonomic reflex tests performed with an automated CAN Analyzer and was not included in the COMPASS-31 composite outcome. Modified Poisson regression with robust variance estimation was used to calculate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs). Overall, 309 participants (46.5%) had COMPASS-31-defined autonomic dysfunction. Orthostatic intolerance was the most common domain, affecting 271 participants (40.8%), followed by gastrointestinal dysfunction in 177 (26.6%) and urinary dysfunction in 123 (18.5%). Separately, 305 participants (45.9%) met the analyzer-based criteria for CAN. In the multivariable analysis, autonomic dysfunction was more prevalent among participants without a family history of diabetes (aPR = 1.37, 95% CI: 1.16-1.61; p < 0.001), those with diabetes duration of ≥ 10 years (aPR = 1.45, 95% CI: 1.14-1.75; p < 0.001), those not using oral hypoglycemic agents (aPR = 1.66, 95% CI: 1.39-1.97; p < 0.001), and those who rarely consumed vegetables or consumed one portion per day (aPR = 1.79, 95% CI: 1.37-2.34; p < 0.001). Approximately half of the adults with T2DM in this tertiary-care population had COMPASS-31-defined autonomic dysfunction. Higher prevalence was associated with no family history of diabetes, longer diabetes duration, non-use of oral hypoglycemic agents, and lower vegetable intake. These findings highlight the potential value of symptom-based autonomic assessment and support further prospective research to better understand the clinical and lifestyle factors associated with autonomic dysfunction among adults with T2DM in Zanzibar.

PubMedDisability and health journal2026-10-20

Sexual and reproductive health service receipt among sexually active adolescent and young adult men by race and ethnicity and disability status.

Zionskowski Kelsey K, Hoyle Jessica J, Stevens J Dalton JD, Valentine Anne A et al.

Little is known about receipt of sexual and reproductive health (SRH) services among adolescent and young adult men with disabilities or by race and ethnicity. To examine differences in SRH service receipt by disability status, race, and ethnicity. We analyzed 2011-2019 National Survey of Family Growth data for sexually active men aged 15-25 (n = 4802). Groups reflected disability status and race and ethnicity, with non-Hispanic White men without disabilities as the reference. Modified Poisson regression was used to estimate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs). Men with disabilities had similar or higher receipt of the SRH services examined. Compared with non-Hispanic White men without disabilities, non-Hispanic White men with disabilities had higher prevalence of STI testing (aPR, 1.80; 95% CI, 1.42-2.28) and being asked about type of sex (aPR, 1.58; 95% CI, 1.34-1.88). Hispanic men with disabilities had higher prevalence of being asked about type of sex (aPR, 2.10; 95% CI, 1.65-2.68) and receiving family planning services (aPR, 1.62; 95% CI, 1.30-2.01). Non-Hispanic Black men with disabilities had the highest service receipt, including STI testing (aPR, 2.56; 95% CI, 2.39-2.74) and being asked about condom use (aPR, 2.11; 95% CI, 1.65-2.70). Contrary to expectations, men with disabilities across racial and ethnic groups had higher SRH service receipt than non-Hispanic White men without disabilities. However, receipt remained low, with fewer than one-third receiving many recommended services, indicating missed opportunities to provide SRH care.

PubMedCurrent pharmaceutical design2026-10-20

Design, In Silico Targeting, and Characterization of Curcumin-Ibuprofen Prodrug Microspheres for Brain-Specific Delivery in Alzheimer's Therapy.

Kumari Priya P, Sathyanarayanan Arulmozhi A, Pimpalkar Kunal K, Kumar Ajay A et al.

Alzheimer's Disease (AD) is a complex neurodegenerative condition characterized by limited treatment effectiveness, attributed to inadequate Blood-Brain Barrier (BBB) permeability and low medication absorption. Curcumin and ibuprofen possess anti-inflammatory and neuroprotective properties but are limited by pharmacokinetic constraints. This study aimed to synthesize a curcumin-ibuprofen mutual prodrug (CIP), formulate it into chitosan-based microspheres (CIPM), and evaluate its neuroprotective potential for brain-targeted delivery in AD. CIP was synthesized via ethylenediamine carbodiimide (EDCI) mediated esterification and confirmed through IR, NMR, LC-MS, and DSC. CIPM microspheres were prepared using emulsion crosslinking, characterized by scanning electron microscopy, drug entrapment efficiency (85.5%), zeta potential, particle size analysis, and DSC. In silico tools (SwissADME, ProTox-II) and molecular docking were used to assess ADMET profiles and target binding (AChE, BACE1, β-secretase). Network pharmacology identified overlapping targets between curcumin and AD. In vivo evaluation was conducted in a TMT (Trimethyltin)- induced neurodegeneration rat model through behavioral Morris Water Maze (MWM), Novel Object Recognition (NOR), Social Recognition Test (SRT), and biochemical and histological assessments. CIP demonstrated strong binding affinity with AD-related targets (-10.0 to -8.5 kcal/mol) and favorable ADMET properties. Network analysis identified 226 overlapping targets and key hub genes. CIPM significantly improved cognitive performance, antioxidant enzyme levels, and neuronal integrity compared to individual drugs and showed comparable efficacy to donepezil. The present study demonstrates that the curcumin-ibuprofen conjugate, when delivered through chitosan-based microspheres, effectively enhances brain targeting and overcomes pharmacokinetic barriers. The formulation not only improved drug bioavailability but also showed superior neuroprotective and cognitive benefits compared to individual drugs. Molecular docking and network pharmacology further confirmed its multi-target potential, suggesting a synergistic mechanism in modulating key AD pathways. These outcomes highlight CIPM as a promising candidate that warrants further pharmacokinetic and clinical validations for Alzheimer's therapy. The curcumin-ibuprofen prodrug-loaded microspheres present a promising brain-targeted treatment approach for Alzheimer's disease by improving bioavailability, engaging multiple targets, and providing neuroprotection.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ibuprofen